Total Utang marang Modal ADC Therapeutics Corp (ADCT)

ADC Therapeutics SA - logo grafis emiten ADCT

ADC Therapeutics (ADCT) is optimizing expenses by outsourcing drug manufacturing and clinical trials to third-party contractors. Business revenues are based on the sale of ZYNLONTA for lymphoma therapy. The implementation of automated laboratory systems is accelerating genetic analysis. The price action for the total debt-to-equity ratio is 0.00, as clearly illustrated in the chart below for ADCT.

adctherapeutics.com (ADCT): Rasio Utang marang Ekuitas saka 04.07.2022 nganti 30.10.2026

Rincian metrik lan analitis perusahaan ADC Pharma (ADCT)

- rega saham lan konsensus proyeksi valuasi:
Rega saham ADC Therapeutics SA|ADCT - Target konsensus
- rincian kapitalisasi pasar:
Kapitalisasi pasar ADC Therapeutics|ADCT - Nilai Perusahaan
- indikator kapitalisasi buku:
Aset Bersih saben Siji Saham ADC Therapeutics|ADCT - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku adctherapeutics.com|ADCT - Gunggung Aset Perusahaan
- rincian utang lan likuiditas:
Total Utang marang Modal ADC Therapeutics|ADCT - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas ADC Therapeutics|ADCT - Kewajiban utang agregat|Utang marang nilai buku ADC Therapeutics|ADCT - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan ADC Therapeutics|Likuiditas cepet adctherapeutics.com
- data bathi resik lan rasio valuasi:
ADCT - Bathi resik perusahaan
Pambiji fundamental perusahaan:ADC Therapeutics SA
Produk dadi ADC Therapeutics

The ratio is calculated as total liabilities divided by equity, providing a real-time assessment of changes in financial stability. This metric determines the extent of the business's reliance on borrowed funds relative to shareholder equity. For ADC Therapeutics (ADCT), leverage is critical when financing robotic laboratories and high-throughput biomolecule screening. A high ratio signals risks of asset impairment. By analyzing the trend of the total debt-to-equity ratio, an investor evaluates the balance between growth and solvency.

Analisis pesaing ADC Therapeutics

TGTX (TG Therapeutics) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas Arcellx Inc (ACLX)|Total Utang marang Modal IRON|Total Utang marang Modal Syndax Corp (SNDX)|Utang marang Ekuitas Kura Oncology, Inc. KURA|FHTX: Rasio Utang marang Ekuitas|Vor Biopharma - Total Utang marang Modal|Nkarta, Inc. (NKTX) - Rasio Total Utang marang Ekuitas|COEP: Total Utang marang Modal|Utang marang Modal Actinium Corp (ATNM)|Utang marang Ekuitas Estrella Immunopharma|CASI: Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas MRKR (Marker Therapeutics)|INAB (IN8bio Inc.) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal ERNA (Eterna Therapeutics Inc.)|GT Biopharma Corporation - Utang marang Ekuitas|APTO - Utang marang Ekuitas|BPTH: Utang marang Ekuitas|MEI Pharma (MEIP) - Utang marang Ekuitas|Utang marang Modal Vincerx Pharma (VINC)